Abstracts Archive - Page 301 of 2425 - ACR Meeting Abstracts

Abstract Number: 2017 • ACR Convergence 2023
Lupus Nephritis Is Strongly Associated with Low Bone Mineral Density and Osteoporosis in Patients with Systemic Lupus Erythematosus
Edgar Wiebe¹, Elisa Schilling², Dörte Huscher³, Andriko Palmowski⁴, Zhivana Boyadzhieva⁵, Sandra Hermann¹, Burkhard Muche¹, Tobias Alexander⁶, Falk Hiepe⁵ and Frank Buttgereit¹, ¹Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany, ³Institute of Biometry and Clinical Epidemiology and Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁶Charité Universiätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for osteoporosis and fragility fractures. This risk is mediated by a variety of factors…
Abstract Number: 1953 • ACR Convergence 2023
Mortality Trends in Polymyositis and Dermatomyositis in Mexico: A General Population-based Study from 2000 to 2019
CLAUDIA MENDOZA PINTO¹, Pamela Munguía-Realpozo¹, Ivet Etchegaray-Morales², Mario García-Carrasco², Paulina Cortés-Hernández¹, Roberto Arreguín-Reyes¹, Jorge Ayón-Aguilar¹ and Gabriel Rodríguez-Castillo², ¹Instituto Mexicano del Seguro Socia, Puebla, Mexico, ²Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Background/Purpose: Patients with polymyositis and dermatomyositis (PM/DM) present multiple complications that may lead to increased mortality rates and data on PM/DM mortality in Mexico is…
Abstract Number: 1826 • ACR Convergence 2023
Investigating the Health Profiles and the Prevalence and Correlates of Cannabis Use Among Patients Accessing Rheumatologic Care in Alberta, Canada
Elaine Yacyshyn, Simran Gulati, Samuel Lowe, Allyson Jones, Tarek Turk, Shelby Yamamoto, Kali Gregg, Linda Kolewaski, Joanne Olson, Pauline Paul and Cheryl Sadowski, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Implications of using cannabis as therapeutics in a growing number of diseases coupled with increasing public awareness are leading to an increase in patient…
Abstract Number: 2060 • ACR Convergence 2023
Creation of a Standardized and Collaborative Transfer Process from Pediatric to Adult Rheumatology
Alana Haussmann¹, Lauren Taylor-Maloney², Ingrid Pan², Katherine Nowicki³, JoAnn Zell⁴ and Katharine Moore⁵, ¹University of Colorado Internal Medicine Residency, Denver, CO, ²Children's Hospital Colorado, Aurora, CO, ³University of Colorado, Lakewood, CO, ⁴University of Colorado Anschutz Medical Campus, Denver, CO, ⁵University of Colorado / Children's Hospital Colorado, Aurora, CO
Background/Purpose: The transfer of care from pediatric to adult rheumatology (AR) is a complex process dependent on communication between medical teams within and across institutions,…
Abstract Number: 2063 • ACR Convergence 2023
Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY): Assessing Behavioral Predictors of Clinical Trial Referrals Among Healthcare Providers
Saira Sheikh¹, Tessa Englund¹, Andrew Simkus², Nicole Wanty³, Annie McNeill⁴, Kristen Holtz⁴, Tenesha Hood⁵, Starla Blanks⁶, Maria Allen⁷ and Allen Anandarajah⁷, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²KDH Research & Communication, Asheville, NC, ³KDH Research & Communication, Marietta, GA, ⁴KDH Research & Communication, Atlanta, GA, ⁵ACR, Atlanta, GA, ⁶American College of Rheumatology, Atlanta, GA, ⁷University of Rochester Medical Center, Rochester, NY
Background/Purpose: The aim of this study is to assess outcomes among healthcare providers in the American College of Rheumatology's (ACR) Training to Increase Minority Enrollment…
Abstract Number: 2066 • ACR Convergence 2023
Ultrasound Guided Synovial Biopsy Course: Achievement of Learner Self Efficacy
Diane Horowitz¹, Darren Tabechian², Ami Ben-Artzi³, Karina Torralba⁴ and Arthur Mandelin⁵, ¹Northwell Health, Great Neck, NY, ²University of Rochester Medical Center, Rochester, NY, ³Ami Ben Artzi, MD, San Diego, CA, ⁴Loma Linda University, Loma Linda, CA, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Ultrasound guided synovial biopsy (UGSB) is a minimally invasive, safe and effective tool to obtain synovium for clinical and research purposes. Described in Europe…
Abstract Number: 2069 • ACR Convergence 2023
Navigating the Residency-to-Fellowship Transition in Rheumatology
Lilian Otalora Rojas¹ and Gurjit S Kaeley², ¹University of Florida, Ponte Vedra Beach, FL, ²University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL
Background/Purpose: Transitioning from residency to fellowship is a significant milestone in a medical professional's career. Physicians acquire foundational knowledge and skills during residency, while fellowship…
Abstract Number: 2067 • ACR Convergence 2023
A New Tool Assessing Trainees’ Interventional Musculoskeletal Ultrasound Skills
Stine Maya Dreier Carstensen¹, Lene Terslev², Søren Just³, Mikkel Østergaard⁴, Mogens Pfeiffer-Jensen¹ and Lars Konge⁵, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Copenhagen University Hospital – Rigshospitalet Glostrup, Copenhagen, Denmark, ²Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ³Section of Rheumatology, Department of Medicine, Odense University Hospital – Svendborg Hospital, Odense, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ⁵Copenhagen Academy for Medical Education and Simulation The Capital Region of Denmark, Copenhagen, Denmark
Background/Purpose: Interventional musculoskeletal ultrasound (MSUS) procedures, such as ultrasound-guided arthrocentesis and joint injections, are routinely used in rheumatology practice. However, the efficacy and safety of…
Abstract Number: 1205 • ACR Convergence 2023
Universal Social Determinants of Health Screening in a Pediatric Rheumatology Specialty Clinic: A Feasibility Study
Mia Chandler¹, Margart Taggart², Maria Alfieri², Olha Halyabar³, Joyce Chang², Mary Beth Son⁴ and Melissa Hazen², ¹Boston Children's Hospital, Milton, MA, ²Boston Children's Hospital, Boston, MA, ³Children's Hospital/Boston Medical Center, Newton, MA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Social determinants of health (SDoH) significantly impact health outcomes. Practice guidelines from a national pediatric organization and federal agencies recommend routine assessment of SDoH.…
Abstract Number: 1813 • ACR Convergence 2023
Assessing Immunogenicity of SARS-CoV-2 Vaccine Neoantigen S1 in Autoimmune Rheumatic Disease Patients: A Study on Cellular and Humoral Responses
Inés Pérez Sancristóbal¹, Maria Paula Alvarez Hernandez¹, kauzar Mohamed Mohamed², Maria Rodriguez Laguna¹, Cristina Martinez³, Esther Toledano³, Dalifer Freites⁴, Benjamin Fernandez¹, María Rodero³, Cecilia Bravo³, Antonia Rodrígez de la Peña⁵, Silvia Sanchez - Ramon⁵, Gloria mato Chain⁶ and Gloria Candelas¹, ¹Hospital Clinico San Carlos, Madrid, Spain, ²Department of Immunology, Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Clinico San Carlos, Rheumatology Deparment, Madrid, Spain, ⁴Hospital Clínico San Carlos, Madrid, Spain, ⁵Department of Clinical Immunology, IML and IdSSC, Hospital Clínico San Carlos, Madrid, Spain, ⁶Department of Preventive Medicine, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Data on cellular and humoral immunogenicity triggered by SARS-CoV-2 vaccines in patients with autoimmune rheumatic diseases (ARD) are limited. While current vaccine efforts have…
Abstract Number: 1301 • ACR Convergence 2023
The Relationship Between Socioeconomic Factors and Persistent Active Rheumatoid Arthritis: Results from (NEIAA) a Large UK Cohort of Early Inflammatory Arthritis
Maryam Adas¹, Sam Norton¹, Andrew Cope¹, Maya Buch², James Galloway¹ and Elena Nikiphorou¹, ¹King's College London, London, United Kingdom, ²University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Psychosocial factors may interplay with biological factors to drive a refractory disease state in patients with inflammatory arthritis1. We aim to explore which socioeconomic,…
Abstract Number: 1259 • ACR Convergence 2023
Voices Unheard: Unmasking the Hidden Challenges of Youth with Rheumatic Diseases
Natasha Trehan¹, Laurie Proulx² and Isabel Dukes³, ¹University of Ottawa, Take a Pain Check Foundation, Toronto, ON, Canada, ²Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, ³CAPA & TAPC, Freelance, Ottawa, ON, Canada
Background/Purpose: Rheumatic disease doesn't merely present physical challenges—it also significantly impacts various psychological and social aspects of one's life, often disrupting academic progress, straining friendships,…
Abstract Number: 1311 • ACR Convergence 2023
T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Sumei Tang¹, Gong Cheng¹, Yingni Li¹, Yun Li¹, Feng Sun¹, Xiaolin Sun¹, Jiahui Cheng¹, Ru Li¹ and Zhanguo Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…
Abstract Number: 1822 • ACR Convergence 2023
The Food and Drug Administration’s (FDA’s) Safety Surveillance of Baricitinib and Tocilizumab for COVID-19 (Disclaimer: This Abstract Reflects the Views of the Authors and Not Necessarily Those of the US FDA)
Laura Kangas¹, Lisa Wolf², Maya Beganovic³, Rachna Kapoor⁴, James Kidd⁴, Kate McCartan⁴, Kim Swank⁴ and Ida-Lina Diak⁴, ¹Food and Drug Administration, Bethesda, MD, ²Food and Drug Administration, Chevy Chase, MD, ³Food and Drug Administration, Chicago, IL, ⁴Food and Drug Administration, Silver Spring, MD
Background/Purpose: Baricitinib, a Janus kinase inhibitor, and tocilizumab, an interleukin-6 receptor antagonist, are two products first approved for the treatment of rheumatoid arthritis. Notably, these…
Abstract Number: 1833 • ACR Convergence 2023
Development of a Polygenic Risk Model for Therapeutic Response to Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) in Fibromyalgia Based on Polygenic Single Nucleotide Polymorphism (SNP)-Count Scores
Jeffrey Rosenfeld¹, Greta Linse², Sally Slipher², Candace Flint³, Annie Iserson³, Herbert Harris⁴, Jean Engels³, Gregory Sullivan⁵ and Seth Lederman⁶, ¹Tonix Pharmaceuticals, Chatham, NJ, ²Montana State University, Bozeman, MT, ³Tonix Pharmaceuticals, New York, NY, ⁴Tonix Pharmaceuticals, Chapel Hill, NC, ⁵Tonix Pharmaceuticals Inc, Chatham, NJ, ⁶Tonix Pharmaceuticals, South Dartmouth, MA
Background/Purpose: Fibromyalgia (FM) is characterized by widespread pain, non-restorative sleep, fatigue, and cognitive dysfunction. TNX-102 SL is a sublingual cyclobenzaprine tablet designed for daily use…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].